Together, these findings unveil a new anti‐fibrotic pathway, involving PRDM16, TRPA1, MAPK and TGF‐β1, that is activated in renal tubule cells in early DKD to keep fibrosis at a low level. Here, PRDM16 is linked to diabetic kidney disease.